What adjustments should be made to the medication regimen of an elderly female patient with hypertension, chronic kidney disease stage three, pulmonary fibrosis, and osteoarthritis, who is currently on metoprolol succinate ER 25 mg once a day and losartan potassium 50 mg one time a day, and has elevated blood pressures?

Management of Uncontrolled Hypertension in Elderly Patient with CKD Stage 3

Direct Recommendation

Increase losartan from 50 mg to 100 mg once daily as the first step, then add a thiazide-like diuretic (chlorthalidone 12.5-25 mg daily) if blood pressure remains ≥140/90 mmHg after 2-4 weeks. 1, 2, 3

---

Step 1: Optimize Current ARB Dosing

• Uptitrate losartan to 100 mg once daily before adding additional agents, as the current 50 mg dose is submaximal and the FDA-approved maximum dose for hypertension is 100 mg daily 1
• The patient's blood pressure of 150/70 mmHg represents uncontrolled stage 1 hypertension requiring treatment intensification, with systolic BP 20 mmHg above the minimum target of <140/90 mmHg 4, 2
• Losartan 100 mg has demonstrated superior blood pressure reductions compared to 50 mg in clinical trials, with mean decreases of 5.5-10.5/3.5-7.5 mmHg at the higher dose 1, 5
• In CKD stage 3, losartan remains safe and effective without dose adjustment, as pharmacokinetics are minimally altered even in end-stage renal disease 6, 7

---

Step 2: Add Thiazide-Like Diuretic if BP Remains Uncontrolled

• If blood pressure remains ≥140/90 mmHg after 2-4 weeks on losartan 100 mg, add chlorthalidone 12.5-25 mg once daily to achieve guideline-recommended dual therapy 4, 2, 3
• Chlorthalidone is strongly preferred over hydrochlorothiazide because it provides greater 24-hour blood pressure reduction (especially overnight), has a longer therapeutic half-life, and has superior cardiovascular outcomes data 4, 2
• The combination of ARB + thiazide diuretic is particularly beneficial in CKD stage 3, providing both blood pressure control and renoprotection 8, 6
• Adding hydrochlorothiazide 12.5 mg to losartan 50 mg produces placebo-adjusted blood pressure reductions of 15.5/9.2 mmHg, demonstrating the additive benefit of combination therapy 1

---

Step 3: Third Agent if Needed

• If blood pressure remains uncontrolled on losartan 100 mg + chlorthalidone, add amlodipine 5-10 mg once daily to create guideline-recommended triple therapy (ARB + thiazide + calcium channel blocker) 2, 3, 9
• This combination targets three complementary mechanisms: renin-angiotensin system blockade, volume reduction, and vasodilation 2, 9
• Avoid adding metoprolol as a third agent unless there are compelling indications (heart failure with reduced ejection fraction, post-MI, angina), as beta-blockers are less effective than calcium channel blockers for stroke prevention and cardiovascular events in hypertension 4, 2

---

Critical Monitoring Parameters

• Check serum potassium and creatinine 2-4 weeks after adding chlorthalidone to detect hypokalemia or changes in renal function 2, 3
• Monitor for hyperkalemia when uptitrating losartan, especially in CKD stage 3, though this risk is lower with concurrent diuretic use 2, 6
• Target blood pressure is <140/90 mmHg minimum, ideally <130/80 mmHg given the patient's CKD 4, 2, 9
• Reassess blood pressure within 2-4 weeks after each medication adjustment, with the goal of achieving target BP within 3 months 2, 3, 9

---

Essential Considerations Before Medication Changes

• Verify medication adherence first, as non-adherence is the most common cause of apparent treatment resistance 4, 2
• Review for interfering medications: NSAIDs are particularly problematic in osteoarthritis patients and should be avoided or minimized, as they significantly interfere with blood pressure control and worsen renal function 4
• If analgesics are necessary for osteoarthritis, acetaminophen is preferable to NSAIDs, though it provides minimal anti-inflammatory benefit 4
• Reinforce sodium restriction to <2 g/day, which provides additive blood pressure reductions of 5-10 mmHg 4, 2, 9

---

Special Considerations for This Patient

• The isolated systolic hypertension pattern (150/70 mmHg) is common in elderly patients and responds well to thiazide diuretics and calcium channel blockers 4
• In CKD stage 3, thiazide diuretics remain effective as long as creatinine clearance is >30 mL/min; if creatinine clearance falls below 30 mL/min, switch to a loop diuretic like torsemide 4
• Pulmonary fibrosis is not a contraindication to any of the recommended antihypertensive agents, though ACE inhibitors should be avoided if cough develops (ARBs like losartan do not cause cough) 5
• The current metoprolol dose (25 mg) is subtherapeutic for blood pressure control; however, rather than increasing metoprolol, prioritize optimizing losartan and adding a diuretic, as beta-blockers are not first-line for uncomplicated hypertension 4, 10

---

Fourth-Line Agent for Resistant Hypertension

• If blood pressure remains ≥140/90 mmHg despite losartan 100 mg + chlorthalidone 25 mg + amlodipine 10 mg, add spironolactone 25 mg daily as the preferred fourth-line agent 4, 2, 3
• Spironolactone provides additional blood pressure reductions of 20-25/10-12 mmHg when added to triple therapy, addressing occult volume expansion that commonly underlies treatment resistance 4, 2
• Monitor potassium closely when adding spironolactone to losartan, as hyperkalemia risk is significant with dual renin-angiotensin system and aldosterone blockade 4, 2

---

Common Pitfalls to Avoid

• Do not combine losartan with an ACE inhibitor, as dual RAS blockade increases adverse events (hyperkalemia, acute kidney injury) without additional cardiovascular benefit 4, 2
• Do not use non-dihydropyridine calcium channel blockers (diltiazem, verapamil) if the patient develops heart failure, as they have negative inotropic effects 4, 2
• Do not delay treatment intensification—the patient has uncontrolled hypertension requiring prompt action to reduce cardiovascular risk 4, 2
• Do not increase metoprolol as the primary strategy for blood pressure control in this patient without compelling cardiac indications 4, 2